Tesamorelin signals your pituitary to release growth hormone in its natural rhythm, and the fat around your organs responds to that signal first.
If your waistline has kept expanding while your training and nutrition stayed consistent, the constraint may be a hormone signal rather than a habit. Visceral fat responds to different biology than the fat you can pinch.
BEST FOR
Adults with excess visceral fat and documented growth hormone decline
METHOD
Subcutaneous injection, self-administered
FREQUENCY
Once daily, protocol length set by your provider
All information regarding products and services on this site are for educational purposes only. Dynamis Online is not a pharmacy and does not manufacture, distribute, or ship any medications discussed on this site. Our licensed medical professionals work with you to develop a personalized treatment plan that fits your unique health goals. All products and medications are manufactured and distributed by independent, third-party vendor pharmacies and are routinely inspected by both state and federal agencies for safety and efficacy.
Visceral fat cells carry more growth hormone receptors than subcutaneous fat cells, so they respond preferentially to the GH signal. The pivotal 26-week trial measured roughly a 15% to 18% reduction in visceral adipose tissue by CT imaging.
Muscle area increased in clinical subjects rather than declining, which separates this from calorie-restriction approaches that shed lean tissue alongside fat.
Trial data documented triglyceride reductions and improvements in cholesterol ratios, alongside the change in body composition.
Because your pituitary does the releasing, the hypothalamic-pituitary feedback loop stays intact. Patients commonly report deeper sleep, which is when the largest GH pulses occur.
Tesamorelin is a synthetic 44-amino-acid analog of growth hormone-releasing hormone (GHRH). It was FDA-approved in 2010 under the brand name Egrifta to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. Use for age-related visceral fat is off-label and provider-directed, which is why it belongs in a monitored protocol rather than a self-sourced one.
Rather than adding growth hormone from outside, tesamorelin prompts your pituitary to release its own in a pulsatile pattern. Your liver then produces IGF-1, the downstream signal that drives fat metabolism and lean tissue change. At Dynamis, tesamorelin is offered as part of our Peptide Programs alongside CJC-1295, a longer-acting GHRH analog that extends the window of stimulation. Protocols are built for men and women and adjusted on individual labs and hormone profiles, not on gender.
Our board-certified providers order baseline IGF-1, fasting glucose, HbA1c, and a full lipid panel, plus body composition measurement. These numbers establish whether tesamorelin fits your physiology and where your starting point actually is.
The FDA-approved dose is 2 mg once daily for the original Egrifta formulation and 1.4 mg once daily for Egrifta SV. Your provider sets your dose, protocol length, and whether CJC-1295 belongs alongside it, based on your labs rather than a fixed formula.
You self-administer a small subcutaneous injection, rotating sites across the abdomen. Your dedicated Health Coach handles questions on timing, technique, and what you are noticing week to week.
Follow-up labs at 8 to 12 weeks confirm your IGF-1 response and track glucose, since growth hormone can affect insulin sensitivity. Your provider adjusts from there, and body composition testing replaces the scale as the measure that matters.
Tesamorelin targets visceral fat, the fat surrounding your internal organs, which is metabolically distinct from the subcutaneous layer you can pinch. The pivotal trial measured a 15% to 18% reduction in visceral adipose tissue over 26 weeks. It does not reduce subcutaneous fat and it is not a general weight-loss drug, so imaging and labs come first to confirm that visceral fat is what you are actually dealing with.
The most common effects are injection-site reactions, joint pain, fluid retention, and muscle pain, and most are mild and settle as your body adjusts. The one area requiring active monitoring is blood sugar, since growth hormone elevation can affect glucose metabolism, so fasting glucose and HbA1c are tracked throughout. Tesamorelin is contraindicated in active malignancy, pituitary disorders, pregnancy, and disrupted hypothalamic-pituitary function, and your provider reviews all of these before you start.
HGH delivers synthetic growth hormone directly, bypassing your pituitary and suppressing your own production over time. Tesamorelin signals your pituitary to release GH in its natural pulsatile pattern, which keeps the feedback loop intact. Most providers consider that preserved feedback loop the safer long-term structure for body composition goals, and your provider will help you weigh the two against your labs.
Sermorelin is a shorter 29-amino-acid GHRH fragment, gentler and lower cost, and more often used for general anti-aging and sleep support. Ipamorelin works through a different receptor entirely as a ghrelin mimetic, with a broader recovery and muscle-preservation profile. Tesamorelin carries the strongest visceral fat evidence of the three, so the right choice depends on your hormone panel, your body composition, and what you are trying to change.
Visceral fat returned to baseline within roughly 26 weeks of discontinuation in the pivotal trial. Tesamorelin stimulates your own GH production rather than permanently changing how fat is stored, so results depend on staying on protocol. Your provider structures protocol length and any breaks around your labs and goals, and reviews that plan with you before you start rather than after.
